Precigen Announces Departure Of Chief Financial Officer >PGEN

03-31 04:05

Precigen Reports CFO, Rick Sterling, To Step Down; Co. Commenced Search For Successor

03-31 03:12

Precigen Announces First Patient Dosed For PRGN-2012 AdenoVerse Immunotherapy In Patients With Recurrent Respiratory Papillomatosis

03-23 19:12

BRIEF-Precigen Receives FDA Orphan Drug Designation For Prgn-2012 Adenoverse Immunotherapy In Patients With Recurrent Respirato

03-18 20:55

Precigen Gets FDA Orphan Designation for PRGN-2012 in Recurrent Respiratory Papillomatosis >PGEN

03-18 20:54

Precigen Received FDA Orphan Drug Designation for Adenoviral Vector Expressing HPV 6 and HPV 11 Antigens for Treatment of Recurrent Respiratory Papillomatosis

03-18 06:07

BRIEF-Precigen Reports Q4 Revenue Of $19.3 Mln

03-02 06:15

Recap: Precigen Q4 Earnings

03-02 05:54

Precigen Q4 EPS $(0.22) Misses $(0.17) Estimate, Sales $19.30M Beat $16.96M Estimate

03-02 05:09

Precigen started at buy with $13 stock price target at Stifel Nicolaus

02-25 21:36